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Prostate surgery can improve lower urinary tract symptoms (LUTS) by relieving bladder 
outlet obstruction (BOO). However, surgery is less effective without BOO, or if detrusor 
underactivity (DU) is present. Urodynamics (UDS) can identify BOO and measure detrusor 
activity, but evidence in clinical practice is lacking. UPSTREAM (Urodynamics for Prostate 
Surgery Trial: Randomised Evaluation of Assessment Methods) evaluated whether a care 
pathway including UDS would reduce surgery without increasing urinary symptoms.   
Design, setting and participants  
UPSTREAM is a pragmatic, non-inferiority randomised controlled trial in 26 hospitals in 
England (ISRCTN56164274) in men with bothersome LUTS where surgery was an option.  
Intervention 
Participants were randomised (1:1) to routine care (RC) diagnostic tests, or routine care plus 
urodynamics (UDS).  
Outcome measures 
The primary outcome was International Prostate Symptom Score (IPSS; patient reported 
outcome scale from 0 to 35 points) 18-months post-randomisation, with a non-inferiority 
margin of one point. Urological surgery rates were a key secondary outcome.  
Statistical analysis 
The primary outcome was compared between the arms using linear regression, analysed on 
an intention-to-treat basis.  
Results and limitations  
Between October 2014 and December 2016, 820 men (median age 68 years) were 
randomised (393 and 427 in RC and UDS arms, respectively). The UDS arm showed non-
inferiority of mean IPSS scores (UDS 12·6; RC 13.1; adjusted difference at 18 months -0·33 
(95% CI -1·47, +0·80)). In the UDS arm, 153/408 (38%) received surgery compared with 
138/384 (36%) for RC (adjusted OR 1·05; 95% CI 0·77, 1·43). 428 adverse events (UDS 






In this population, the UDS randomised group was non-inferior to RC for IPSS but did not 
reduce surgical rates. The study shows that routine use of UDS in evaluation of 
uncomplicated LUTS has a limited role and should be used selectively.   
Patient summary 
For men with uncomplicated lower urinary tract symptoms, the symptom improvements after 
treatment and the number of operations done are similar, whether or not urodynamic tests are 
done in addition to routine tests. Accordingly, routine use of UDS has a limited role in this 






Lower urinary tract symptoms (LUTS) are associated with substantial personal and societal 
costs, and detrimental impact on quality of life (QoL) 1-4. Potential mechanisms contributing 
to LUTS include benign prostate obstruction (BPO) and weakened bladder muscle (detrusor 
underactivity; DU), which both give similar voiding symptoms 5. In addition, overactive 
bladder (OAB) 6,7 and nocturnal polyuria may cause storage LUTS 8. Guidelines indicate to 
offer interventional treatment, e.g. TURP, if LUTS are severe and unresponsive to 
conservative treatment 9,10. Symptom scores, bladder diary, physical examination, urinalysis 
and uroflowmetry (maximum flow rate (Qmax) and post void residual (PVR)) are routinely 
used for LUTS assessment 9,11. However, none of these tests can distinguish BPO from DU. 
Since only LUTS due to BPO is reliably expected to improve with surgery 12, the routine 
assessments leave uncertainty for recommending therapy. 
Urodynamics (UDS) uses pressure flow studies (PFS) to distinguish BPO from DU, by 
associating a slow Qmax with either high detrusor pressure or low detrusor pressure 
respectively 13. High pressure generating slow flow is diagnostic for BPO, as quantified by 
the BOO Index (BOOI). DU severity can be quantified using the Bladder Contractility Index 
(BCI) 14. UDS also includes filling cystometry to assess storage function, which can identify 
detrusor overactivity (DO). However, due to lack of evidence 9,11,15,16, guidelines do not 
routinely include UDS. Using UDS could avoid “unnecessary” surgery in men whose voiding 
LUTS is actually caused by DU. However, UDS also has costs and involves catheterisation, 
potentially without changing the management recommendation. Thus, there is considerable 
regional variation in use of UDS (from 0.2 to 5.0 tests annually per 1000 population) 17. 
Gaining meaningful evidence to improve male LUTS assessment is an identified priority 9,11. 
UPSTREAM (Urodynamics for Prostate Surgery Trial: Randomised Evaluation of 
Assessment Methods) is a randomised controlled trial (RCT) of men with bothersome LUTS 
referred to urology departments in 26 UK hospitals, where surgery was being considered 18. 
All men had received  conservative and/ or medical therapy, and had sufficiently bothersome 
LUTS to enter the secondary care diagnostic pathway to consider whether surgical 
intervention was indicated. UPSTREAM was powered to ascertain non-inferiority in 
symptom severity (International Prostate Symptom Score (IPSS)) at 18-months post-






Study design and participants 
The trial protocol and statistical analysis plan (SAP) are published elsewhere 18,19. To 
summarise, UPSTREAM is a pragmatic, two-arm, multicentre, non-inferiority RCT to 
determine the clinical and cost-effectiveness of UDS for diagnosis and management of BOO 
in men (≥18-years) with bothersome LUTS, where surgery was potentially being considered. 
Exclusion criteria were; catheter use for bladder emptying, relevant neurological disease, 
current treatment for prostate or bladder cancer, previous prostate surgery, unfit for surgery, 
and/or unwilling to comply with trial requirements. Baseline characteristics and initial 
diagnostic testing outcomes are reported separately 20. UPSTREAM was approved by the 
NHS Research Ethics Service (South Central – Oxford B, reference 14/SC/0237). The study 
was overseen by an independent Data Monitoring Committee and Trial Steering Committee. 
The trial was registered with the International Standard Randomised Controlled Trial Number 
(ISRCTN) registry on 8 April 2014 (ISRCTN56164274) and sponsored by North Bristol 
NHS Trust (NBT; reference number 3250). 
 
Procedures 
Men were randomised to undergo either routine non-invasive tests set out in the applicable 
NICE Guideline 9 (Routine Care arm; control), or the routine tests supplemented by UDS 
(UDS arm; intervention). Given the pragmatic design, research centres could conduct 
additional ‘discretionary’ tests (e.g. PSA testing, cystoscopy, prostate volume measurement) 
20. Once men had undergone assessments, a treatment recommendation was made by the 
surgeon, and the patient decided whether to accept the treatment recommendation. No 
specific management pathway requirements were imposed by the trial. The primary outcome 
was captured at 18-months post-randomisation.  
 
Randomisation and masking 
Simple randomisation, without stratification or minimisation techniques, was employed via a 
telephone/web-based system hosted by Bristol Randomised Trials Collaboration (BRTC). 




were not blinded to randomised allocation. The research team (co-applicants) were blinded to 
study arm throughout recruitment and analyses, however, the junior trial statistician was 
unblinded to allow reporting to the Data Monitoring Committee. 
 
Outcomes 
Data were collected between October 2014 and August 2018, with details of outcome 
measures published elsewhere 18-20. In brief, the primary outcome was the difference in IPSS 
between the two arms at 18-months post-randomisation 21,22, with a non-inferiority margin of 
one-point. Scores could range from 0-35, with higher scores reflecting more severe 
symptoms. The IPSS was incorporated into a patient-completed questionnaire booklet, 
provided at 0- (baseline), 6-, 12-, and 18-months, collected via paper copy, online, or 
telephone call with trained central team staff. The key secondary outcome was surgery rates 
(proportion of men in each study arm having surgery) within 18-months of randomisation. 
Surgical data were obtained via case report forms (CRFs) completed by trained hospital staff 
from medical record review.  
An additional secondary outcome was the relative harms of UDS, and subsequent treatment, 
as measured by adverse events (AEs); see the protocol paper for definitions 18. Events related 
to surgical treatment were classified by sites using the Clavien-Dindo classification 22, 
reviewed by an independent clinician. Other patient reported outcome measures (PROMs), 
namely the International Consultation on Incontinence Questionnaire for MLUTS (ICIQ-
MLUTS) and associated sexual matters (ICIQ-MLUTSsex) were included within the 
questionnaire booklets. IPSS-QoL was also measured (scored 0-6, with higher scores 
reflecting worse QoL). ICIQ three-day bladder diary were completed at baseline and 18-
months, and men who had UDS were asked to complete the ICIQ-UDS-Satisfaction 
questionnaire.  
Clinical outcomes (including DRE, uroflowmetry (Qmax, VV and PVR), UDS and additional 
tests) were also obtained via CRFs completed by hospital staff from medical records. 
Additional uroflowmetry data were collected for men who underwent surgery, approximately 
4-months after surgery (+/- 1-month). The method (quality) of UDS testing is reported 
elsewhere 18. An internal validation of surgery recommendations was carried out after the 
trial (post-hoc), by the trial office, whereby data on uroflowmetry and urodynamics were 







Statistical analyses were conducted as per the published SAP 19, using STATA software, 
version 15.1 23. All primary and secondary comparative analyses adopted the intention-to-
treat principal, with no imputation for missing data, adjusting for centre and the relevant 
baseline measure. To avoid perfect prediction, binary PROMS were not adjusted by centre. 
All analyses, comparing arms, used Routine Care as the reference group so that findings 
could be interpreted as the effect of including UDS in the patient pathway.  
The primary analysis, IPSS score at 18-months, was compared between the arms using linear 
regression, adjusting for centre and baseline IPSS score. The sample size required to test for 
non-inferiority was set at 800 men, to allow for a non-inferiority margin of one-point, 
standard deviation of five-points, attrition of 20% and power of 80%. Non-inferiority was to 
be declared if the upper limit of the two-sided 95% CI, comparing UDS to Routine Care, was 
less than one-point. More details on the sample size calculation and non-inferiority margin 
can be found in the published SAP 19. 
As sensitivity analyses, a per protocol and complier average causal effect model (CACE) 
were carried out to ensure the intention-to-treat model results were robust. The per protocol 
analysis restricted the primary comparison to only include those who received their assigned 
treatment. The CACE analysis utilised the same patients as the primary analysis but used 
allocation in an instrumental variable analysis. Further details on the additional sensitivity 
analyses carried out can be found in the supplementary appendix.  
All sub-group analyses for the primary outcome were prespecified in the published SAP 19. 
To assess the effect of storage dysfunction, a binary variable separated nocturia more than 
once per night from nought to once. IPSS questions 2 (frequency), 4 (urgency) and 7 
(nocturia) were combined and the median was used to split the sample into high/low storage 
dysfunction severity groups. An additional post-hoc analysis examined interaction between 
treatment allocation and surgery on change in IPSS score, to explore whether surgery was 
more effective in one of the treatment groups. Change in IPSS score was used, instead of 
adjusting for baseline IPSS, to avoid the selection bias caused by the differing baseline 




used to compare linear regression models with and without an interaction between treatment 
arm and surgery. 
AEs were explored at the event level and patient level on an ‘intention-to-treat’ and ‘as-
treated’ basis.  
  
Results 
Between 01 October 2014 and 31 December 2016, 8671 men were screened (see 20) and 820 
were recruited (Figure 1); median age was 68 years and 67% had comorbidities. Baseline 
characteristics were similar between the study arms (Table 1), as detailed elsewhere 20. Of the 
427 men randomised to the UDS arm, 353 (83%) had UDS during the 18-months of follow 
up. Of the 393 men randomised to Routine Care, 28 (7%) received UDS. There were 67 
withdrawals, 39 (9%) and 28 (7%) for the UDS and Routine Care arms respectively; the most 
common reason was poor health. After adjustment for baseline IPSS, the analysable sample 
at 18-months was 641 (78%); 328 (77%) and 313 (80%) for the UDS and Routine Care arms, 
respectively, with similar loss to follow up of the primary outcome (Figure 1). 
 
Primary outcome of IPSS 
The UDS arm demonstrated non-inferiority for patient reported LUTS, compared with 
Routine Care at 18-months, with a difference in mean IPSS of -0·33 (95% CI -1·47, 0·80); 
below the 1.00 non-inferiority margin (Table 2). The CACE analyses of IPSS results were 
generally similar to the ITT results. The upper confidence interval in the per protocol 
analysis was 1.05, slightly above the non-inferiority margin (Table 2). The patients in the 
Routine Care arm who received urodynamics (n=24) had higher IPSS scores at 18-months 
than compliers (n=305) in the routine care arm (17.3 vs 12.8), although this is a small sample 
size to base this on and the difference was also evident at baseline (22.6 vs. 19.2).  
Other sensitivity analyses were also generally in agreement with the ITT analyses 
(Supplementary Table 1) and further details can be found in the supplementary appendix.    
Pre-specified tests of interaction explored potential effect modifiers. Although underpowered, 
there were no evident interactions between subgroups, such as age or urinary function, on the 





Secondary clinical outcomes 
The hypothesised reduction in surgery rates in the UDS arm was not shown at 18-months. 
38% of men (153/408) in the UDS arm received surgery during the 18-month period, 
compared with 36% (138/384) in the Routine Care arm, OR 1.05 (95% CI 0.77, 1.43) (Table 
3). Likewise, the proportions of men offered surgery were 49% (196/397) versus 48% 
(182/378) respectively, (OR 1·02; 95% CI 0·76, 1·38). The post-hoc internal validation of 
surgery recommendations also gave figures that suggested equal proportions in the two arms, 
with 65% of men being recommended in both ‘as treated’ arms (Supplementary Table 3). 
Median time between randomisation and surgery was 216 days in the UDS arm (IQR 141-
327 days) compared with 177 days in the Routine Care arm (IQR 106-284 days). In both 
groups at least 75% of men had TURP, and the remainder underwent a laser procedure, 
bladder neck incision, Urolift or another procedure.  
In all men reporting IPSS, mean scores decreased from 18·5 (n=403) at baseline to 12·6 
(n=340) at 18-months in the UDS arm and from 19·4 (n=371) to 13·1 (n=329) in the Routine 
Care arm (Tables 1 and 2). In an exploratory post-hoc analysis, there was some evidence to 
suggest that UDS was an effect modifier of surgery, with surgery being potentially more 
beneficial in the Routine Care arm, p<0.001 (Figure 2, Supplementary Table 4).  
 
Secondary patient-reported outcomes 
The mean difference for the IPSS QoL score was -0·07 (95% CI -0·32, 0·18), slightly lower 
in the UDS group, with an interval that excludes the minimal clinically important difference 
(MCID) of 0·5 (Table 4). Mean IPSS QoL scores dropped from an average of 4.1 to 2.7 in 
the UDS arm and 4.2 to 2.7 in the Routine care arm. Other urinary outcomes were similar, 
with general improvement across all symptoms by 18-months (Supplementary Table 5). 
There was some evidence to suggest nocturia (more than once per night) improved more in 
the UDS arm, although this may have been a chance finding, given the number of 
comparisons of secondary outcomes. Sexual patient reported outcomes were similar, and the 
proportion of patients experiencing sexual symptoms at 18-months were similar to the levels 
seen at baseline (Supplementary Table 5). There was no evidence to suggest a difference 






In total, there were 428 AEs in the UPSTREAM study, 234 in the UDS arm and 194 in the 
Routine Care arm. There was no evidence to suggest that one study arm was superior to the 
other for AEs per individual (Supplementary Table 6a). At the event level, the number of 
related SAEs was similar across the two arms (Supplementary Table 6b). There were slightly 
more events overall in the UDS arm, largely due to the events that were deemed related to 
UDS (for example, urinary tract infection). There were 11 deaths during the 18-months of 
follow up, 9 of which were in the UDS arm; all were deemed unrelated to diagnostic testing 
or treatment.  
 
Discussion 
The primary outcome showed that a pathway of routine care including UDS, and the 
subsequent treatment, was non-inferior to Routine Care in terms of symptomatic urinary 
outcome. This was a population of men who had bothersome LUTS despite first line therapy, 
and were being considered for surgical treatment. We hypothesised that by identifying DU, 
UDS would reduce surgery rates, but such a reduction was not identified. UPSTREAM 
provides robust, high-level clinical evidence regarding use of UDS for male LUTS, which is 
something that literature reviews had identified as missing 9,15,24. In our systematic review 15, 
we found evidence from one single-centre trial suggesting that UDS changed the 
management of LUTS and that men receiving clinical assessment alone were more likely to 
undergo surgery. No difference was noted between groups in the IPSS before and after 
intervention, so we concluded that evidence regarding the value of UDS was insufficient. 
Likewise, the UK NICE Clinical Guideline on LUTS in men: management (CG97) indicated 
that future research should clarify whether UDS could improve outcome of surgery, by 
identifying which patients had BOO. The UPSTREAM study responds to that call, and 
supports a position that properly-applied Routine Care testing provides sufficient assessment 
of LUTS when considering surgery in men comparable to the trial population.  
UDS evidently remains important in some male LUTS settings. The qualitative evaluation we 
undertook identified a key reason for men wanting to undergo urodynamics was perceiving 




information. Furthermore, some men experienced deterioration in symptoms despite surgery, 
and we plan to identify any predisposing characteristics in upcoming analyses. The study 
excluded men if they had a relevant neurological disease, or had previously undergone 
prostate surgery. In these groups there may be a higher prevalence of DU 12,26, indicating that 
UDS has a role.    
The non-inferiority design was chosen since it was hypothesised that surgery rates would be 
lower in the UDS arm, due to the ability to exclude LUTS due to DU. In these cases, surgery 
might not be effective or could make the man’s overall health worse (for example, due to 
complications such as incontinence). However, the key secondary outcome measure of 
surgery rates also showed no difference in the UDS and Routine Care arms, at 38% and 36% 
respectively. To explore this further, the rates at which surgeons recommended surgery were 
captured. In addition, an internal exercise was undertaken matching source data to a checklist 
of parameters for considering surgery (Supplementary table 3). These likewise found no 
difference between arms in potential surgery recommendation. In order to evaluate crossover 
between arms, a CACE analysis was undertaken to allow unbiased assessment of treatment 
effect, after separating the intervention arm into compliers and non-compliers. The CACE 
analyses of IPSS results were generally similar to the ITT results. Thus, the lack of difference 
between arms is not resulting from issues of crossover or decision-making, and can be 
supported objectively.  
On inspection of the interaction between surgery and treatment allocation, there was evidence 
to suggest that surgery in the Routine Care arm led to larger drops in IPSS score. This may be 
due to delayed surgery in the Urodynamics arm, hampering the long-term benefits of surgery, 
or perhaps it indicates that other diagnostic tests may be better at identifying patients where 
surgery may be beneficial. Long term follow up could provide the answer. Quality of testing 
clearly could influence the conclusions, so we undertook a quality control exercise which we 
reported previously 27. In brief, we found several errors of standardisation, testing, 
interpretation and equipment maintenance. Generally these had a relatively low risk of 
adverse implications for decision making. However, erroneous diagnosis of BOO was 
identified in 5.5% of tests, which is a serious error of interpretation, due to the risk of 
undergoing “unnecessary” surgery. 
The overall rates of surgery were lower than anticipated when the study was designed. The 




trials. Nonetheless, trends in lower likelihood for surgeons to recommend surgery, and for 
patients to accept surgery, progressed during the timescale of the study 28,29. There was no 
evident signal of any difference in surgery rates to suggest an underpowered study. Thus, 
whilst there was a lower rate of surgery than planned for, it does not affect this study’s 
conclusion.  
The high number of men screened to identify the study population was determined by the 
clinical setting from which identified potential recruits were identified. Where sites screened 
in general urology clinics, in which eligible LUTS cases were a minority, a large number of 
patients was screened. This does not impact on the study interpretation, as the patient 
population is clearly defined by the eligibility criteria. 
We identified there was variability in the therapeutic pathway across the 26 hospitals. For 
example, several patients had not fully completed their LUTS treatment at 18 months, or had 
completed it relatively recently. Clinically, a 12-month timeframe after surgery is appropriate 
to establish response. Thus, a longer-term follow up of participants could provide complete 
surgery rates in both arms, and symptomatic outcomes. The AEs occurred in rates similar to 
those seen in other surgical randomised trials 30. There was a slight predominance in the UDS 
arm, consistent with the known rates of complications for UDS testing. There were 11 deaths, 
but these did not result from study-related procedures or interventions, as confirmed by an 
independent reviewer. 
While adherence to the study arms was reasonable, there was a slightly higher likelihood of 
men crossing over from the UDS arm to the Routine Care arm. This may suggest some 
unwillingness to contemplate an examination which involves catheterisation. However, for 
those men who actually underwent UDS, the overall satisfaction rates with testing were very 
high, as we reported previously 20,25. The additional time of contact with healthcare 
professionals might explain the high satisfaction levels; qualitative research identified the 
value of clear and personalised interpretation of symptoms in helping the man come to terms 
with his LUTS and decide on treatment, regardless of treatment 25. Research centres were 
permitted to conduct additional ‘discretionary’ tests (e.g. PSA testing, cystoscopy), as these 
were not considered influential on relative indications for urodynamic testing. 
Going forward, we believe that future research should focus on individual predictive factors 
influencing outcome of surgery. We observed that some patients did not have a good 




whether any diagnostic feature anticipated bad outcome with surgery; establishing features to 
anticipate detrimental effect of surgery is a priority. Research should also extend the range of 
potential participants to cover co-morbidities, including people with a background of 
neurological impairments. We also anticipate publishing the health economic findings in due 
course.  
In identifying that the UDS pathway was non-inferior to Routine Care for symptom 
outcomes, but without a concomitant reduction in surgery rates, the UPSTREAM trial 
establishes that Routine Care provides sufficient testing for assessing LUTS when 
considering surgery in men comparable to the trial population. Urology departments can now 
move towards an evidence-based reduction of UDS. This must be in the context of reliable 
capture and interpretation of the Routine Care evaluations (history and examination, 
symptom score, bladder diary, urinalysis, uroflowmetry) 27. Notably, there remains a clear 
expression by individual patients that they are keen to have access to maximum information 
to advise their decision-making 25. Thus, delivery of UDS is not supported as a service-level 
approach to reducing surgery rates, but is desirable for an individualised approach responsive 
to supporting decision-making.  
 
Conclusions 
Including UDS in the diagnostic tests for male LUTS resulted in a non-inferior symptom 
outcome (IPSS) to routine care, 18-months post-randomisation. It did not, however, influence 
rates of surgery for treating BOO. Results of this study do not support routine use of UDS for 
men with suspected BOO. However, the large number of men who saw modest symptom 
change, or evident deterioration, suggests the need to interrogate the diagnostic pathway 
further, particularly for predictive features to identify men at risk of poor outcome. 
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